Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bee Venom for CKD-MBD in Hemodialysis Patients
NCT06901102Phase 2Not yet recruiting
- Sponsor
- Mansoura University
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in Chronic kidney disease mineral bone disorder (CKD-MBD), sponsored by Mansoura University. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
Chronic kidney disease mineral bone disorder (CKD-MBD)
Beyond the preview
Go deeper on NCT06901102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901102.